A biodegradable chitosan-based hydrogel extended the effective delivery of the neuroprotective peptide NX210c from under 1 hour to over 10-15 days, achieving drug exposure dozens of times higher than intravenous injection.
AUC dozens of times higherThe hydrogel delivery achieved drug exposure (area under the curve) dozens of times greater than IV injection, sustaining peptide levels for 10-15 days from a single subcutaneous injection.
What the researchers found
The chitosan-DOTAGA hydrogel formed in situ under physiological conditions via electrostatic and hydrogen bonding interactions, requiring no solvents. Pharmacokinetic comparison in rodents showed dramatic differences:
- IV injection: peptide cleared within 1 hour
- Free subcutaneous NX210c: eliminated within approximately 3 hours
- Hydrogel delivery: peptide levels sustained for 10-15 days with area under the curve (AUC) dozens of times higher than IV
In vivo studies confirmed subcutaneous injectability, gelation ability, biocompatibility, and complete biodegradation within a few weeks.
Why it matters
Many therapeutic peptides fail clinically not because they don't work, but because they're cleared from the body too quickly. This hydrogel technology addresses one of the biggest barriers in peptide therapeutics — short half-life — converting a treatment requiring continuous hospital-based IV infusion into a simple subcutaneous injection lasting weeks. If applicable to other peptides, this platform could make many promising peptide drugs clinically viable.
How the study worked
Researchers developed chitosan-based hydrogels functionalized with the DOTAGA macrocyclic ligand. Hydrogel candidates were screened in vitro for injectability, gelation properties, peptide loading capacity, and release kinetics. In vivo validation was performed in rodents, assessing subcutaneous injectability, gel formation, biocompatibility, and biodegradation. Pharmacokinetic studies compared NX210c blood levels after IV injection, free subcutaneous injection, and hydrogel-mediated subcutaneous delivery.
What this study cannot tell us
Therapeutic efficacy of NX210c delivered via the hydrogel was not assessed — only pharmacokinetics were evaluated. The biodistribution and brain penetration of sustained-release NX210c were not reported. Long-term safety of repeated hydrogel injections was not studied. The DOTAGA functionalization adds regulatory complexity. Scale-up from laboratory to clinical manufacturing was not addressed. Only rodent models were used.
How to read the evidence
This is a preclinical development study in rodents demonstrating proof-of-concept for the delivery platform. Pharmacokinetic data are compelling, but therapeutic efficacy and human translation remain to be demonstrated.
When this study was published
Published in 2026, this is very recent work addressing a persistent challenge in peptide drug delivery with a practical, clinically compatible solution.
The bigger picture
Short half-life is the Achilles' heel of peptide therapeutics. While GLP-1 agonists solved this through fatty acid conjugation and PEGylation, many other therapeutic peptides remain impractical due to rapid clearance. Injectable hydrogel depots represent an alternative sustained-release strategy that could be broadly applicable. This work is particularly relevant for neurotherapeutics, where sustained brain exposure is often needed for clinical benefit.
Questions still open
- Does the sustained-release profile translate to sustained neuroprotective efficacy for NX210c?
- Can this hydrogel platform be adapted for other short-lived therapeutic peptides beyond NX210c?
- How do patients experience the subcutaneous hydrogel depot — is there local irritation or discomfort as it degrades?
Common questions
How does the hydrogel solve the short half-life problem of peptide drugs?
What is NX210c and what could it treat?
Read the original research
Smart zwitterionic biodegradable hydrogel for sustained peptide delivery: Application to the neurotherapeutic peptide NX210c.
Biomaterials advances, 178, 214437
Citation
Rosson, Elise; Thomas, Eloise; Sidi-Boumedine, Jacqueline; Kryza, David; Couderc, Marie; Brichart, Thomas; Geloen, Alain; Montembault, Alexandra; David, Laurent; Lux, François; Godfrin, Yann; Tillement, Olivier. (2026). Smart zwitterionic biodegradable hydrogel for sustained peptide delivery: Application to the neurotherapeutic peptide NX210c.. Biomaterials advances, 178, 214437. https://doi.org/10.1016/j.bioadv.2025.214437